

CITATION REPORT

List of articles citing

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

DOI: 10.18632/oncotarget.7277

Oncotarget, 2016, 7, 13587-98.

Source: <https://exaly.com/paper-pdf/87799971/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
440	Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes. 2016 , 6,		6
439	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. 2016 , 17,		41
438	Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. 2016 , 11, e0155189		77
437	Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix. <i>Oncotarget</i> , 2016 , 7, 75379-75393	3.3	25
436	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. 2016 , 22, 4309-21		127
435	Next-Generation Sequencing: Role in Gynecologic Cancers. 2016 , 14, 1165-73		8
434	DNA damage response as a therapeutic target in gynecological cancers. 2016 , 28, 404-11		5
433	Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma. 2016 , 46, 935-941		45
432	Emerging roles of p53 and other tumour-suppressor genes in immune regulation. 2016 , 16, 741-750		187
431	Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. 2016 , 22, 5651-5660		91
430	WITHDRAWN: Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. 2016 , 243, 21-28		3
429	Targeting deficient DNA damage repair in gastric cancer. 2016 , 17, 1757-66		10
428	Defects in homologous recombination repair behind the human diseases: FA and HBOC. 2016 , 23, T19-37		19
427	Neoantigens encoded in the cancer genome. 2016 , 41, 98-103		54
426	Leveraging premalignant biology for immune-based cancer prevention. 2016 , 113, 10750-8		44
425	Synthetic lethality: the road to novel therapies for breast cancer. 2016 , 23, T39-55		12
424	Facteurs prédictifs et biomarqueurs précoces de réponse aux inhibiteurs de checkpoint immunologiques (anti-PD-1, anti-PD-L1). 2016 , 18, 533-542		2

423	Cytotoxic and targeted therapy for hereditary cancers. 2016 , 14, 17	32
422	Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. 2016 , 16, 811-26	29
421	When Genome Maintenance Goes Badly Awry. 2016 , 62, 777-87	51
420	What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?. 2016 , 18, 29	16
419	Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. 2017 , 6, e1277308	60
418	PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic. 2017 , 114, 153-165	21
417	Uterine cancer, mutational phenotype, and the era of immune checkpoint blockade. 2017 , 13, 175-180	1
416	Genome variation across cancers scales with tissue stiffness - an invasion-mutation mechanism and implications for immune cell infiltration. 2017 , 2, 103-114	29
415	PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors. 2017 , 41, 334-342	103
414	DNA Damage and Repair Biomarkers of Immunotherapy Response. 2017 , 7, 675-693	331
413	Treatment strategies for DNA repair-deficient prostate cancer. 2017 , 10, 889-898	21
412	Combined immune checkpoint blockade as a therapeutic strategy for -mutated breast cancer. 2017 , 9,	167
411	Precancer Atlas to Drive Precision Prevention Trials. 2017 , 77, 1510-1541	81
410	CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer. 2017 , 145, 436-445	26
409	Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. 2017 , 103, 44-51	56
408	Optimizing treatment in recurrent epithelial ovarian cancer. 2017 , 17, 1147-1158	73
407	[Abnormalities of DNA repair and gynecological cancers]. 2017 , 104, 971-980	1
406	Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer. 2017 , 86, 5-14	28

405	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. 2017 , 15, 205	13
404	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. 2017 , 3, e173290	152
403	Mechanisms regulating T-cell infiltration and activity in solid tumors. 2017 , 28, xii18-xii32	175
402	Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. 2017 , 30, 1622-1632	41
401	Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives. 2017 , 59, 109-116	83
400	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. 2017 , 24, 311-331	299
399	DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. 2017 , 8, 1751	300
398	Gene-expression profiling to predict responsiveness to immunotherapy. 2017 , 24, 134-140	55
397	Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. 2017 , 144, 72-76	21
396	Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer. 2017 , 28, e64	31
395	Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy. 2017 , 8, 1679	113
394	Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?. 2017 , 8, 1848	58
393	Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. 2017 , 10, 2539-2551	30
392	Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. 2017 , 17, 657	29
391	Erratum to Genetic and molecular changes in ovarian cancer. 2017 , 14, 196-201	2
390	The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. <i>Oncotarget</i> , 2017 , 8, 15621-15631	104
389	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. <i>Oncotarget</i> , 2017 , 8, 41641-41669	3-3 13
388	The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others. 2018 , 99, 552-560	23

387	TNF α and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. 2018 , 7, e1412902	64
386	PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. 2018 , 124, 2498-2506	56
385	Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. 2018 , 4,	11
384	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. 2018 , 11, 475-486	52
383	PARP inhibitors and breast cancer: highlights and hang-ups. 2018 , 3, 83-94	3
382	Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. 2018 , 110, 787-790	82
381	Reprogramming T-cells for adoptive immunotherapy of ovarian cancer. 2018 , 18, 359-367	5
380	Sensitive and frequent identification of high avidity neo-epitope specific CD8 T cells in immunotherapy-naive ovarian cancer. 2018 , 9, 1092	82
379	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. 2018 , 10, 643-655	9
378	An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers. 2018 , 40, 372-388	12
377	From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation. 2018 , 118, 933-935	25
376	The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma. 2018 , 42, 183-191	38
375	Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. 2018 , 24, 777-783	112
374	Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. 2018 , 69, 333-347	28
373	Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. 2018 , 118, 312-324	137
372	DNA Repair Deficiency and Immunotherapy Response. 2018 , 36, 1710-1713	22
371	Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians. 2018 , 7, 703-715	91
370	Current and Future Developments of PARP Inhibitors in the Treatment of Breast and Ovarian Cancer. 2018 , 10,	

369	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. <i>Oncotarget</i> , 2018 , 9, 28561-28571	3-3	92
368	The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer. 2018 , 28, 1514-1519		13
367	Sustainable Response of a Patient With Metastasized Pancreatic Cancer and a Hypermutational Phenotype to Immunotherapy. New Therapeutic Concept for a Rare Subtype?. 2018 , 2, 1-6		1
366	and mutation status associates with and expression in ovarian cancer. <i>Oncotarget</i> , 2018 , 9, 17501-17511	3-3	54
365	Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. <i>Oncotarget</i> , 2018 , 9, 7949-7960	3-3	41
364	Review of Immune Therapies Targeting Ovarian Cancer. 2018 , 19, 74		32
363	Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer. 2018 , 32, 997-1010		17
362	The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies. 2018 , 19, 70		12
361	Complete pathological response following neoadjuvant FOLFOX chemotherapy in BRCA2-mutant locally advanced rectal cancer: a case report. 2018 , 18, 1253		6
360	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. 2018 , 6, 141		132
359	Development of PARP and Immune-Checkpoint Inhibitor Combinations. 2018 , 78, 6717-6725		106
358	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. 2018 , 10, 93		77
357	Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. 2018 , 43, 1014-1032		86
356	Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. 2018 , 73, e450s		45
355	The DNA damage response in immunotherapy and radiation. 2018 , 3, 527-533		18
354	Novel Systemic Treatments in High Grade Ovarian Cancer. 2018 ,		
353	Undifferentiated Endometrial Carcinoma, an Immunohistochemical Study Including PD-L1 Testing of a Series of Cases From a Single Cancer Center. 2018 , 37, 564-574		12
352	Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome. 2018 , 80, e12975		12

351	Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors. 2018 , 52, 253-258	5
350	Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma. 2018 , 22, 3979	28
349	IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1. 2018 , 31, 1513-1522	50
348	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. 2018 , 3, 635-643	40
347	Personalising Treatment for High-Grade Serous Ovarian Carcinoma. 2018 , 30, 515-524	10
346	Combination immune checkpoint blockade as an effective therapy for mesothelioma. 2018 , 7, e1494111	22
345	Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics. 2018 , 10,	24
344	Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. 2018 , 15, 639-650	108
343	The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy. 2018 , 10,	58
342	Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report. 2018 , 11, 3705-3711	3
341	Nivolumab use for gene mutation carriers with recurrent epithelial ovarian cancer: A case series. 2018 , 25, 98-101	19
340	Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. 2018 , 10, 1758835918786658	73
339	Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. 2018 , 29, 1366-1376	76
338	The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. 2018 , 9, 3292	96
337	Targeting the Microenvironment in High Grade Serous Ovarian Cancer. 2018 , 10,	14
336	Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1. 2018 , 42, 1216-1223	25
335	Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers. 2018 , 8, 8990	19
334	PARP Inhibition to Enhance Response to Chemotherapy. 2019 , 231-257	

333	Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor. 2019 , 84, E318-E333	18
332	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. 2019 , 36, 2638-2678	86
331	Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer. 2019 , 37, 2386-2397	12
330	Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. 2019 , 20, 1306-1315	52
329	Combining PARP inhibition with PD-1 inhibitors. 2019 , 20, 1196-1198	3
328	Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer. 2019 , 5, 524-528	34
327	Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review. 2019 , 9,	65
326	Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation. 2019 , 17, e909-e912	1
325	Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. 2019 , 7, 183	134
324	DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. 2019 , 14, 1640-1650	36
323	Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. 2019 , 10, 1337	63
322	Immunotherapy in Ovarian Cancer. 2019 , 28, 447-464	17
321	Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. 2019 , 155, 262-269	11
320	Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: Opportunities for PARP-Like Inhibitors and Immunotherapy. 2019 , 10,	5
319	Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response. 2019 , 11,	22
318	Prospects for combining immune checkpoint blockade with PARP inhibition. 2019 , 12, 98	63
317	Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8 T cells compared with women with BRCA wild-type disease during the early disease course. 2019 , 18, 3914-3924	3
316	Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer. 2019 , 12, 7193-7201	8

315	The BRCA2 mutation status shapes the immune phenotype of prostate cancer. 2019 , 68, 1621-1633	19
314	Clonal Evolution of c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC). 2019 , 8,	3
313	Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines. 2019 , 70, 395-407	34
312	Ovarian Cancer Immunotherapy: Turning up the Heat. 2019 , 20,	76
311	DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies. 2019 , 80, 59-84	15
310	Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers. 2019 , 1999, 3-29	1
309	Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches. 2019 , 20,	12
308	Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed. 2019 , 39, e126-e140	19
307	Veliparib: a new therapeutic option in ovarian cancer?. 2019 , 15, 1975-1987	5
306	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. 2019 , 39, 147-164	248
305	Variant classification in precision oncology. 2019 , 145, 2996-3010	28
304	Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. 2019 , 30, 1080-1087	237
303	BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer. 2019 , 19, 387	12
302	Genetic counseling referral for ovarian cancer patients: a call to action. 2019 , 18, 303-309	4
301	Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. 2019 , 14, e0215381	43
300	Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?. 2019 , 153, 213-214	1
299	Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy. 2019 , 9, 156	67
298	Women@ cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics. 2019 , 13, 904	7

297	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. 2019 , 8,	4
296	Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma. 2019 , 9, 3235	38
295	Tailoring Ovarian Cancer Treatment: Implications of Mutations. 2019 , 11,	34
294	Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading. 2019 , 20, 35	32
293	Expression of miR-26b in ovarian carcinoma tissues and its correlation with clinicopathology. 2019 , 17, 4417-4422	4
292	Rucaparib in the landscape of PARP inhibition in ovarian cancer. 2019 , 19, 437-446	1
291	Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. 2019 , 20, 1035-1045	12
290	Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial. 2019 , 37, 1179-1187	21
289	BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. 2019 , 450, 88-97	21
288	Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. 2019 , 153, 217-222	13
287	Mechanistic link between DNA damage sensing, repairing and signaling factors and immune signaling. 2019 , 115, 297-324	12
286	Base excision repair regulates PD-L1 expression in cancer cells. 2019 , 38, 4452-4466	42
285	Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. 2019 , 9, 1853	98
284	Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date. 2019 , 12, 11497-11506	6
283	Is there a role for immunotherapy in ovarian cancer?. 2019 , 7, S276	1
282	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. 2019 , 24, 1340-1347	43
281	Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review. 2019 , 05, 01-18	
280	Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. 2019 , 9, 1289	6

279	Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. 2019 , 11,	23
278	Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer. 2019 , 69, 2048-2060	41
277	Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide. 2019 , 17, e365-e368	1
276	Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer. 2019 , 58, 363-370	16
275	Medikamentöse Therapie des Ovarialkarzinoms in der Primär- und Rezidivsituation. 2019 , 25, 131-144	
274	PARP inhibitors in ovarian cancer. 2019 , 73, 1-9	110
273	Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?. 2019 , 343, 103753	108
272	Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). 2019 , 38, 157-170	22
271	Role of the DNA damage response in prostate cancer formation, progression and treatment. 2020 , 23, 24-37	13
270	Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. 2020 , 156, 488-497	27
269	Targeting DNA repair in cancer: current state and novel approaches. 2020 , 77, 677-703	35
268	Understanding genetic determinants of resistance to immune checkpoint blockers. 2020 , 65, 123-139	3
267	The double-edged sword of cancer mutations: exploiting neoepitopes for the fight against cancer. 2020 , 35, 69-78	1
266	Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours. 2020 , 122, 483-490	6
265	Optimizing immunotherapy for gynecologic cancers. 2020 , 32, 1-8	16
264	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. 2020 , 26, 2704-2710	12
263	Biomarkers for Response to Immune Checkpoint Blockade. 2020 , 4, 331-351	13
262	Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs. 2020 , 26, 651-663	11

261	Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status. 2020 , 39, 558-566	4
260	An Emerging Regulatory Role for the Tumor Microenvironment in the DNA Damage Response to Double-Strand Breaks. 2020 , 18, 185-193	16
259	DNA Damage and Cancer Immunotherapy: A STING in the Tale. 2020 , 80, 21-28	55
258	New approaches for targeting platinum-resistant ovarian cancer. 2021 , 77, 167-181	13
257	Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. 2020 , 261, 118434	6
256	Inflammation and immunity in ovarian cancer. 2020 , 15, 56-66	3
255	Are antiangiogenics a good partner for immunotherapy in ovarian cancer?. 2020 , 23, 543-557	7
254	Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice. 2020 , 20, 678	8
253	Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer. 2020 , 30, 1034-1042	2
252	The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers. 2020 , 21,	17
251	BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives. 2020 , 12,	5
250	Mutations in and differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. 2021 , 1, 1188-1203	43
249	Case Report: Double Germline Mutations in and in a Patient With Mixed Serous-Endometrioid Endometrial Carcinoma. 2020 , 7, 581982	
248	Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs. 2020 , 12,	6
247	A Roadmap Toward the Definition of Actionable Tumor-Specific Antigens. 2020 , 11, 583287	8
246	Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis. 2020 , 12, 1758835920967241	12
245	The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer. 2020 , 12,	5
244	PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma. 2020 , 44, 1050-1060	12

243	PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers. 2020 , 12, 1758835920944116	12
242	A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. 2020 , 26, 5462-5476	14
241	Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets. 2020 , 12, 10423-10437	0
240	Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors. 2020 , 3, e2025109	33
239	DNA Repair and Signaling in Immune-Related Cancer Therapy. 2020 , 7, 205	8
238	Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. 2020 , 10, 18190	4
237	Pathology of Hereditary Breast and Ovarian Cancer. 2020 , 10, 531790	11
236	Development of new medical treatment for epithelial ovarian cancer recurrence. 2020 , 9, 1149-1163	3
235	Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. 2021 , 77, 127-143	21
234	Is There a Role for Immunotherapy in Prostate Cancer?. 2020 , 9,	25
233	Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II. 2020 , 12,	33
232	Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?. 2020 , 34, 749-762	1
231	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. 2020 , 26, 4135-4142	41
230	PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair. 2020 , 40, 1-16	10
229	Therapeutic applications of PARP inhibitors in ovarian cancer. 2020 , 127, 110204	15
228	Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment. 2020 , 147, 2658-2668	5
227	Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma. 2020 , 8,	6
226	Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors. 2020 , 10, 570	56

225	Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas. 2020 , 12,	7
224	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. 2020 , 12,	55
223	Prostate carcinogenesis: inflammatory storms. 2020 , 20, 455-469	38
222	Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma. 2020 , 147, 30-38	7
221	Prognostic value of tumor mutation burden (TMB) and INDEL burden (IDB) in cancer: current view and clinical applications. 2020 , 8, 575	3
220	First-Line Management of Advanced High-Grade Serous Ovarian Cancer. 2020 , 22, 64	9
219	Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer. 2020 , 29, 779-792	3
218	The emerging role of precision medicine in the treatment of ovarian cancer. 2020 , 5, 283-297	3
217	Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer. 2020 , 18, 1315-1325	3
216	Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. 2020 , 16, 1751-1766	10
215	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. 2020 , 11, 1459	82
214	An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers. 2020 , 20, 197	14
213	Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. 2020 , 10,	24
212	Role of DNA repair defects in predicting immunotherapy response. 2020 , 8, 23	21
211	Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. 2020 , 12,	2
210	[The pathology of hereditary ovarian tumors]. 2020 , 40, 85-94	
209	Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition. 2020 , 25, 102169	8
208	Mechanisms of Resistance to PD-1 Checkpoint Blockade. 2020 , 80, 459-465	4

207	ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium. 2020 , 21, 679-686	1
206	[Current advances in immunotherapy in ovarian cancer]. 2020 , 107, 465-473	4
205	Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy. 2020 , 196, 725-735	14
204	PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma. 2020 , 477, 83-91	23
203	Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer. 2020 , 9, 2190-2200	15
202	Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review. 2020 , 73, 191-196	7
201	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. 2020 , 9, 1710389	6
200	TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. 2020 , 27, 841-853	32
199	Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. 2020 , 111, 1676-1684	10
198	Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors. 2020 , 11, e00149	0
197	Replication Stress, DNA Damage, Inflammatory Cytokines and Innate Immune Response. 2020 , 11,	28
196	HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. 2020 , 9, 1744947	15
195	Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy. 2021 , 11, 384-407	18
194	Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. 2021 , 11, 362-383	15
193	Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells. 2021 , 184, 114359	2
192	Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape. 2021 , 160, 279-284	5
191	Clinical and pathological significance of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) expression in high grade serous ovarian cancer. 2021 , 14, 100994	2
190	A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design. 2021 , 22, e63-e66	5

189	Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. 2021 , 18, 215-229	129
188	Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials. 2021 , 13, 17588359211001199	1
187	The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1 tumour-infiltrating lymphocytes. 2021 , 124, 1138-1149	7
186	How to sequence treatment in relapsed ovarian cancer. 2021 , 17, 1-8	1
185	Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids. 2021 ,	
184	Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression. 2021 , 1330, 33-54	1
183	PARP inhibitors in ovarian cancer: An overview of the practice-changing trials. 2021 , 60, 385-397	15
182	Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy. 2021 , 11, 2983-2994	12
181	Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy. 2021 , 13,	5
180	Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?. 2021 , 77, 67-82	5
179	Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. 2021 , 13,	3
178	Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. 2021 , 37, 448-458	3
177	Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines. 2021 , 13,	1
176	PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases. 2021 , 65,	1
175	Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer's Achilles Heel. 2021 , 13,	7
174	Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment. 2021 , 22,	2
173	Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. 2021 , 55, 100744	12
172	The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. 2021 , 9,	1

171	Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?. 2021 , 22,	3
170	PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer. 2021 , 38, 61	0
169	Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer. 2021 , 10, 3045-3058	6
168	Characteristics of Pan-Cancer Patients With Ultrahigh Tumor Mutation Burden. 2021 , 11, 682017	1
167	Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations. 2021 , 22,	2
166	Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer. 2021 , 13,	5
165	Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications. 2021 , 11, 648687	9
164	Differentiation and Regulation of T Cells: A Balancing Act for Cancer Immunotherapy. 2021 , 12, 669474	16
163	Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity. 2021 , 13,	6
162	Harnessing Genomic Stress for Antitumor Immunity. 2021 , 34, 1128-1150	2
161	DNA damage response and PD-1/PD-L1 pathway in ovarian cancer. 2021 , 102, 103112	2
160	Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation. 2021 , 12, 698604	7
159	Frontline Maintenance Treatment for Ovarian Cancer. 2021 , 23, 97	1
158	Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance. 2021 , 20, 1542-1549	2
157	Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival. 2021 , 13,	2
156	Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors. 2021 , 22, 968-976	0
155	Understanding and overcoming resistance to PARP inhibitors in cancer therapy. 2021 , 18, 773-791	31
154	Immunology and Immune Checkpoint Inhibition in Ovarian Cancer - Current Aspects. 2021 , 81, 1128-1144	3

153	Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. 2021 , 36, 109412	12
152	BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer. 2021 , 17, 2817-2830	3
151	Multitumor Case Series of Germline , and -Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors. 2021 , 28, 3227-3239	
150	Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy. 2021 , 13,	1
149	BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking CLU+ CAF expression with HSF1 signaling.	
148	Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. 2021 , 125, 1388-1398	4
147	An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions. 2021 , 9, 347-364	1
146	Molecular Pathology of Ovarian Epithelial Neoplasms: Predictive, Prognostic, and Emerging Biomarkers. 2021 , 14, 415-428	0
145	Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives. 2021 , 13,	4
144	Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers. 2021 , 163, 312-319	1
143	ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. 2021 , 31, 1589-1594	6
142	Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer. 2021 , 7, 114	2
141	Synthetic Lethality in Ovarian Cancer. 2021 , 20, 2117-2128	6
140	Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer. 2021 , 1	0
139	DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer. 2021 , 11, 708294	2
138	Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates. 2021 , 9,	0
137	PARP Inhibitors in Melanoma-An Expanding Therapeutic Option?. 2021 , 13,	2
136	Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. 2021 , 147, 3545-3555	1

135	Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer. 2021 , 11, 703802		0
134	Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists. 2021 ,		1
133	Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. 2021 , 7, 958-970		3
132	Dramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer. 2021 , 46, 1787-1791		
131	Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression. 2021 , 9,		5
130	Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature. 2021 , 11,		15
129	Immune checkpoint inhibitors in ovarian cancer: where do we stand?. 2021 , 13, 17588359211039899		4
128	The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors. 2021 , 15, 1179554921996288		12
127	DNA repair defects and implications for immunotherapy. 2018 , 128, 4236-4242		37
126	Silencing Signal Transducer and Activator of Transcription 3 (STAT3) and Use of Anti-Programmed Cell Death-Ligand 1 (PD-L1) Antibody Induces Immune Response and Anti-Tumor Activity. 2020 , 26, e915854		3
125	Level of tumor-infiltrating lymphocytes and PD status as potential prognostic markers of survival and therapy effectiveness in triple-negative breast cancer. 2020 , 16, 65-70		5
124	Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. <i>Oncotarget</i> , 2016 , 7, 82741-82756	3-3	10
123	Main implications related to the switch to 1/2 tumor testing in ovarian cancer patients: a proposal of a consensus. <i>Oncotarget</i> , 2018 , 9, 19463-19468	3-3	11
122	Soluble forms of immune checkpoint receptor PD-1 and its ligand PD-L1 in plasma of patients with ovarian neoplasms. 2018 , 46, 690-698		2
121	Alterations of DNA damage repair in cancer: from mechanisms to applications. 2020 , 8, 1685		11
120	Biomarkers of immunotherapy in non-small cell lung cancer. 2020 , 20, 139		1
119	Review of Immunogenomics and the Role of Tumor Mutational Burden as a Biomarker for Immunotherapy Response. 2019 , 2, 144-151		3
118	BRCA1/2 Mutations in Salivary Pleomorphic Adenoma and Carcinoma-ex-Pleomorphic Adenoma. 2017 , 7, S155-S162		3

- 117 Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. **2019**, 17, 644-648 10
- 116 Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling. **2020**, 8, e10414 5
- 115 The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers. **2021**, 59-133
- 114 An Introduction to the Current Management of Ovarian Cancer in the Era of Precision Oncology. **2021**, 19-57
- 113 Ovarian Cancer, Early Primary Disease. **2021**, 843-859
- 112 Unboxing the molecular modalities of mutagens in cancer. **2021**, 1 2
- 111 Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application. **2021**, 12, 661115 1
- 110 Mutational cascades in cancer. *Oncotarget*, **2017**, 8, 41784-41785 3.3
- 109 Immune-active microenvironment in small cell carcinoma of the ovary, hypercalcemic type: rationale for immune checkpoint blockade.
- 108 Maintenance Treatment for Recurrent Ovarian Carcinoma | Evidence Supporting the Efficacy and Safety of PARP Inhibitors. **2019**, 15, 29 0
- 107 Application of neoantigens in malignant tumor treatment and prognosis evaluation. **2019**, 27, 287-292
- 106 Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma. **2020**, 8, e9362 0
- 105 Cell-type-specific epigenomic variations associated with BRCA1 mutation in pre-cancer human breast tissues.
- 104 Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. **2021**,
- 103 Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance. **2021**, 33, 19-25 2
- 102 Immunology and Immunotherapy of Ovarian Cancer. **2020**, 487-540
- 101 Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for mutated ovarian cancer?. **2020**, 9, 418-420
- 100 Chromatin-Bound PARP1 Correlates with Upregulation of Inflammatory Genes in Response to Long-Term Treatment with Veliparib.

99	Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer.	
98	DNA Damage Response Genes in Osteosarcoma.. 2021 , 2021, 9365953	0
97	Model constructions of chemosensitivity and prognosis of high grade serous ovarian cancer based on evaluation of immune microenvironment and immune response. 2021 , 21, 593	0
96	Mechanisms of resistance to immune checkpoint inhibitors. 2020 , 28, 857-864	
95	Genomic instability, inflammatory signaling and response to cancer immunotherapy. 2021 , 1877, 188661	8
94	Germinal BRCA-mutation significance in the tumor microenvironment formation Efficacy of PARP inhibition in late-line therapy of metastatic castration-resistant prostate cancer. 2021 , 17, 85-94	
93	Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations.. 2021 , 12, 743073	0
92	Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination.. 2021 , 12, 786286	0
91	Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma. 2021 , 101, 108340	11
90	When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers.. 2022 ,	2
89	Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.. 2022 , 119,	5
88	PARP mediated DNA damage response, genomic stability and immune responses.. 2021 ,	3
87	Cell-type-specific epigenomic variations associated with mutation in pre-cancer human breast tissues.. 2022 , 4, lqac006	
86	Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy.. 2022 , 6, 7	0
85	Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment.. 2022 , 14,	1
84	Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer.. 2022 , 13, 835	2
83	Immunotherapy in Lung Cancer: Current Landscape and Future Directions.. 2022 , 13, 823618	2
82	Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations.. 2022 , 14,	1

81	Clinical and molecular impacts of tumor mutational burden in histological and cytological specimens from cancer patients.. 2022 , 10, 214	
80	Loss and Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer.. 2022 , 6, e2100159	0
79	Multi-Level Analysis and Identification of Tumor Mutational Burden Genes across Cancer Types.. 2022 , 13,	1
78	Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.. 2022 , 14,	0
77	Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?. 2022 , 23,	0
76	The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.. 2022 , 23,	1
75	CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.. 2022 ,	4
74	Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.. 2022 , 11, 2052411	1
73	Identify a DNA Damage Repair Gene Signature for Predicting Prognosis and Immunotherapy Response in Cervical Squamous Cell Carcinoma.. 2022 , 2022, 8736575	0
72	Four-Year Disease-Free Remission in a Patient With POLE Mutation-Associated Colorectal Cancer Treated Using Anti-PD-1 Therapy.. 2022 , 20, 218-223	0
71	PARP Inhibitors Resistance: Mechanisms and Perspectives.. 2022 , 14,	1
70	DNA Damage Response and Cancer Metastasis: Clinical Implications and Therapeutic Opportunities.	0
69	Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study.. 2021 ,	2
68	Oncological Response and Predictive Biomarkers for the Checkpoint Inhibitors in Castration-Resistant Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis.. 2021 , 12,	1
67	Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment.. 2021 , 13,	1
66	The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers.. 2021 , 14, 206	2
65	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges.. 2021 , 14, 109	2
64	Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer.. 2021 , 12, 689076	5

63	Genomic, Immunological, and Clinical Characterization of Pyroptosis in Ovarian Cancer.. 2021 , 14, 7341-7358	1
62	Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1.. 2021 , 11, 795547	5
61	Immunotherapy for Gynaecological Cancers. 2021 , 503-512	
60	PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational Study.. 2021 , 13,	
59	The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention. 2022 , 2, 74-92	
58	DNA damage response and repair in the development and treatment of brain tumors.. 2022 , 924, 174957	
57	Data_Sheet_1.PDF. 2020 ,	
56	Table_1.XLSX. 2020 ,	
55	Ipilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants.. 2022 ,	3
54	Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy.. 2022 ,	1
53	Whole-Genome Sequencing Identifies PPARGC1A as a Putative Modifier of Cancer Risk in BRCA1/2 Mutation Carriers. 2022 , 14, 2350	
52	Chemical complementarity between immune receptor CDR3s and candidate cancer antigens correlating with reduced survival: evidence for outcome mitigation with corticosteroid treatments.. 2022 , 1-9	1
51	A Novel DNA Repair Gene Signature for Immune Checkpoint Inhibitor-Based Therapy in Gastric Cancer. 2022 , 10,	1
50	Homologous recombination deficiency and molecular subtype are associated with immunogenicity in ovarian cancer.	
49	Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma. 2022 , 29, 4185-4198	3
48	Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors. 12,	1
47	Ovarialkarzinom: Immuntherapie, quo vadis?.	
46	Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy. 2022 , 120827	1

45	Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment. 2022 , 22,	
44	Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives. Volume 15, 853-866	1
43	The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. 2022 , 41,	2
42	Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system. 13,	1
41	Research progress of neoantigens in gynecologic cancers. 2022 , 112, 109236	0
40	High expression of CCNB1 driven by ncRNAs is associated with a poor prognosis and tumor immune infiltration in breast cancer. 2022 , 14, 6780-6795	0
39	Homologous Recombination Deficiency Scar: Mutations and Beyond Implications for Precision Oncology. 2022 , 14, 4157	0
38	Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer. 2022 , 14, 4344	0
37	Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.	2
36	High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer. 2022 , 19, 246-256	0
35	THE DNA DAMAGE INDUCED IMMUNE RESPONSE: IMPLICATIONS FOR CANCER THERAPY. 2022 , 103409	0
34	Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes. 2022 , 10, e003744	1
33	Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survival. 13,	0
32	Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome analysis.	0
31	Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints. 2022 , 14, 5332	1
30	Targeting DNA damage response as a potential therapeutic strategy for head and neck squamous cell carcinoma. 12,	1
29	BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling. 2022 , 13,	1
28	Interplay between the DNA Damage Response and Immunotherapy Response in Cancer. 2022 , 23, 13356	1

- 27 Immunotherapy in gynecologic malignancies. **2023**, 506-520.e7 ○
- 26 Adenocarcinoma of the uterine corpus and sarcomas of the uterus. **2023**, 125-174.e30 ○
- 25 Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers. ○
- 24 Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints. **2022**, 14, 5633 ○
- 23 Harnessing immunomodulation during DNA damage in Ewing sarcoma. 12, ○
- 22 Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer. **2022**, 14, 5965 ○
- 21 ncRNA-mediated overexpression of ubiquitin-specific proteinase 13 contributes to the progression of prostate cancer via modulating AR signaling, DNA damage repair and immune infiltration. **2022**, 22, ○
- 20 Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment. 1-14 ○
- 19 Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors. **2022**, ○
- 18 The expression and mutation of BRCA1/2 genes in ovarian cancer: a global systematic study. 1-9 ○
- 17 Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer. ijgc-2022-003941 ○
- 16 Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial. ○
- 15 BRCA1 expression, its correlation with clinicopathological features and response to neoadjuvant chemotherapy in high grade serous ovarian cancer from an Indian centre. ○
- 14 Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors. ○
- 13 Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer. **2023**, 18, e0279590 ○
- 12 The emerging role of MCPH1/BRIT1 in carcinogenesis. 13, ○
- 11 Identification of a Novel Model for Predicting the Prognosis and Immune Response Based on Genes Related to Cuproptosis and Ferroptosis in Ovarian Cancer. **2023**, 15, 579 ○
- 10 PD-1/PD-L1 and DNA Damage Response in Cancer. **2023**, 12, 530 2

- 9 Homologous Recombination Deficiency in Ovarian Cancer: From the Biological Rationale to Current Diagnostic Approaches. **2023**, 13, 284 ○
- 8 Homologous recombination deficiency in triple-negative breast cancer: Multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response. **2023**, 158, 106836 ○
- 7 Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency. **2023**, ○
- 6 In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer. **2023**, 41, 2073-2083 ○
- 5 DNA response and repair gene mutations as a signature for pembrolizumab response in never-smoker non-small lung cancer: real word approach and patient similarity network analysis. ○
- 4 Ovarian Cancer Insights into Platinum Resistance and Overcoming It. **2023**, 59, 544 ○
- 3 The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?. **2023**, 1-32 ○
- 2 The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors. **2023**, 24, 6710 ○
- 1 The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers. **2023**, 24, 7293 ○